Register entry
Boehringer Ingelheim RCV GmbH & Co KG
Data as of · How to read this entry
- Registered sites
- 1
- Active NDC listings
- 17
- Live patents
- 0
- Countries
- 1
- Base
- Austria
Authorisation
Registered operations
Analytical testing1Active ingredient (API) manufacture1
Sites
Registered establishments
1| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Boehringer Ingelheim RCV GmbH & Co KG | Dr. Boehringer Gasse 5-11, Vienna, Austria A1121, Austria (AUT) | Analytical testing, Active ingredient (API) manufacture | 3003433722300010883 |
Catalogue
Drug listings by form and route
1717 active NDC listings: 10 bulk ingredient, 5 vaccine, 2 drug for further processing. By marketing category: BULK INGREDIENT 7, DRUG FOR FURTHER PROCESSING 7, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING 3.
| Dosage form | NDCs |
|---|---|
| liquid | 7 |
| injection, solution | 3 |
| powder, for solution | 3 |
| suspension | 2 |
| powder | 1 |
| solution | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| boehringer ingelheim rcv gmbh & co kg | 17 |
Catalogue
Marketed products
17| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Aldesleukin | powder | 68594-070DRUG FOR FURTHER PROCESSING |
| - | Alteplase | powder, for solution | 68594-090BULK INGREDIENT |
| - | Anakinra | liquid | 68594-050BULK INGREDIENT |
| - | Human Parathyroid Hormone | liquid | 68594-002BULK INGREDIENT |
| - | Human papillomavirus type 11 L1 protein adsorbed | liquid | 68594-008DRUG FOR FURTHER PROCESSING |
| - | Human papillomavirus type 16 L1 protein adsorbed | liquid | 68594-010DRUG FOR FURTHER PROCESSING |
| - | Human papillomavirus type 18 L1 protein adsorbed | liquid | 68594-012DRUG FOR FURTHER PROCESSING |
| - | Human papillomavirus type 6 L1 protein adsorbed | injection, solution | 68594-006BULK INGREDIENT |
| - | Interferon beta-1b | powder, for solution | 68594-080BULK INGREDIENT |
| - | Interferon-gamma-1b | liquid | 68594-020BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | MnB rLP2086 subfamily A protein | suspension | 68594-027DRUG FOR FURTHER PROCESSING |
| - | MnB rLP2086 subfamily B protein | suspension | 68594-028DRUG FOR FURTHER PROCESSING |
| - | Pegvaliase | liquid | 68594-060DRUG FOR FURTHER PROCESSING |
| - | Somatropin | injection, solution | 68594-040BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Teduglutide | solution | 68594-001BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING |
| - | Teriparatide | injection, solution | 68594-030BULK INGREDIENT |
| - | Trastuzumab deruxtecan | powder, for solution | 68594-130BULK INGREDIENT |
Neighbours
Registered in the same town
2- Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.Vienna, AUT
- Valneva Austria GmbHVienna, AUT
Compare
Comparable companies in Austria
- Loba biotech GmbH1 site · 2 NDC
- Fresenius Kabi Austria GmbH2 sites · 4 NDC
- Sandoz Industrial Products S.A5 sites · 441 NDC
- Baxalta US Inc.15 sites · 0 NDC
Enquiry
Common questions
- Is Boehringer Ingelheim RCV GmbH & Co KG FDA approved?
- Boehringer Ingelheim RCV GmbH & Co KG holds 1 FDA-registered establishment in Austria. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Boehringer Ingelheim RCV GmbH & Co KG's drugs manufactured?
- The FDA register lists Vienna. Registered operations: analytical testing, active ingredient (API) manufacture.
- What drugs does Boehringer Ingelheim RCV GmbH & Co KG make?
- 17 products are listed under Boehringer Ingelheim RCV GmbH & Co KG in the openFDA NDC Directory, most often as liquid; injection, solution; powder, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.